Askel Healthcare, a Finland-based MedTech company set to transform surgical knee cartilage treatment and recovery, announced it closed its latest crowdfunding round.
The company shared that 625 investors participated – both new and returning, bringing in €1.76 million.
Related: Oath Surgical raises $24 million for surgical AI ecosystem
Askel Healthcare develops the universal COPLA Cartilage implant: a ground-breaking innovation for the repair of knee cartilage defects. The result of 10+ years of orthopaedic and tissue engineering research at the University of Helsinki and Tampere University in Finland, COPLA is easy to implant and enables a fast recovery, allowing patents to return to an active lifestyle faster.
The funding will help it advance the Class III implant through the clinical phase.
CEO Dr Virpi Muhonen shared on LinkedIn: “A heartfelt thank you for your trust and support. This funding gives us the means to continue advancing toward our next major milestones and to keep the company’s value growth on the right track.”
We recently sat down with Dr Virpi Muhonen and CTO Anne-Marie Haaparanta to discuss their journey and the next steps for the company in our MedTech podcast. Follow us to see more.
